Skip to main content

Author: Johnny Green

Czech Constitutional Court Rules In Favor Of Cannabis Educator In Free Speech Case

This week the Constitutional Court in Czechia ruled in favor of a cannabis magazine and its director, asserting in its ruling that a prior decision by a lower court to convict the journalist and his media outlet violated the country’s free speech laws.

In October 2021, Robert Veverka, a journalist and director of the Czech-based cannabis magazine Legalizace, was targeted over his journalism, with officials accusing him of “inciting and promoting toxicomania.” Legalizace is a bimonthly periodical focused on cannabis and drug policy relating to human rights and environmental issues.

Veverka and his media outlet would later be convicted. Following two court hearings, the district court in Bruntál sentenced Veverka to one year in prison contingent on a two-and-a-half-year probationary period and fined him 50,000 CZK, and after an appeal, the Regional Court in Ostrava upheld the decision, albeit reducing the fine. An appeal to the Highest Court also resulted in an upheld decision.

“The judge mentioned that he is not competent to assess the benefits of the current legislation, the benefits of cannabis products in healthcare, or the negative effects of cannabis use, but that he must base his verdict on the existing legislation which is binding for all. He stated that according to his judgement, Legalizace magazine evidently and factually constituted the criminal offence of inciting and promoting toxicomania.” Veverka stated at the time of the November 2021 verdict in a press release.

“He did not take into account the legislative provisions allowing for cannabis to be handled legally in certain cases or the comprehensive and educational nature of the information published in the magazine. On the contrary, the judge expressed his doubts as to whether the individuals who granted interviews to the magazine were made aware of its content and overall message. Personally, I consider the verdict to be very biased and severely restrictive of the freedom of expression, the right to express political opinion, and the right to information,” Veverka also stated.

As first reported on LinkedIn by fellow Czech journalist and cannabis advocate Lukas Hurt, Robert Veverka later appealed the lower courts’ decisions, and the Czech Republic’s Constitutional Court overturned the lower court’s ruling.

“We didn’t expect much from the Constitutional Court, but Robert had to try – for freedom of speech and for the freedom of our plant. To everyone’s surprise, yesterday, the Court issued a landmark ruling.” Lukas Hurt stated in his social media post.

“Without open and free debate – even on controversial issues such as substance abuse – democracy cannot function effectively…The dissemination of information related to the issue of cannabis use, including criticism of current legal status, is a contribution to the social debate on issues of public interest.” the Constitutional Court stated in its landmark ruling.

Cannabis advocates in Czechia are urging lawmakers to modernize the nation’s cannabis policies. More information about their proposal can be found at: www.racionalniregulace.cz

Two Berlin Districts Want To Launch Cannabis Pilot Trials In 2025

Germany’s approach to cannabis legalization implementation is multi-phased. The first phase of German legalization, often referred to as ‘pillar 1,’ took effect earlier this year. As of April 1st, 2024, adults in Germany can cultivate and possess a personal amount of cannabis. Additionally, cultivation associations became legal starting on July 1st, 2024.

‘Pillar 2’ of German legalization involves launching regional adult-use cannabis commerce pilot trials. Two districts in Berlin, Germany’s largest city, announced plans this week to launch their pilot trials next year.

“The Berlin districts of Friedrichshain-Kreuzberg and Neukölln want to start selling cannabis through several specialist stores next year.” the city announced today on its website. “This is made possible by a pilot project that will be scientifically monitored. Customers who want to buy cannabis must take part in the scientific study and register, the districts announced on Wednesday. They must also be resident in one of the two districts.”

“The sale is organized by a company that buys the cannabis from legal producers in Germany or abroad and sells it on to registered consumers in specialist stores.The two districts, Humboldt University and the Danity Group company signed a letter of intent to this effect on Wednesday.” the city also stated (translated from German to English).

“The application for approval of the project is to be submitted to the relevant federal authority as soon as possible. The sale could begin next summer, it was said.” city officials concluded.

As we previously reported, Germany took a major step forward this week in implementing pilot trials by announcing that the Federal Office for Agriculture and Food will help oversee the nation’s adult-use cannabis research projects, part of which includes pilot trials.

“By passing the Consumer Cannabis Act, the Bundestag has given the Federal Ministry of Food and Agriculture (BMEL) was given the task of appointing the responsible body for processing research applications on consumer cannabis and industrial hemp. The regulation that has now been issued – the Consumer Cannabis Science Responsibility Regulation – stipulates that the Federal Office for Agriculture and Food will examine corresponding research applications and monitor the approved projects.” the German government stated in a news release (translated from German to English).

“Previously, this task was carried out by the Federal Institute for Drugs and Medical Devices (BfArM). The BfArM remains the responsible authority for research into medical cannabis.” German officials also stated.

Israel Government Offers Co-Financing For Participation At International Cannabis Business Conference Berlin 2025

The Ministry of Economy and Industry of Israel has included the International Cannabis Business Conference in Berlin 2025 as an event for which companies can receive co-financing for the cost of exhibiting or participating.

The grant falls under the Foreign Trade Administration’s “Growth for the World” program, allowing Israeli entities to apply for and reimburse up to 4K euros for expenses related to participation/exhibition at the Berlin conference, which is Europe’s largest and longest-running cannabis B2B event.

Applications to participate in the program can be submitted until December 17, 2024 at 5:00 PM. Prospective applicants can apply at this link here. The International Cannabis Business Conference is noted under the ‘Med & Bio’ category in the list of conferences for which companies can receive grants.

The Berlin conference could not be timelier, with Germany’s legal cannabis industry currently undergoing a historic expansion. Starting on April 1st, 2024, cannabis became legal for adults to cultivate, possess, and consume in Germany. Additionally, as of July 1st, 2024, aspiring cultivation association operators can apply with their local regulatory authorities in Germany.

“Europe is by far the most exciting place on the planet for cannabis policy and industry right now. Germany is leading a continental revolution and creating opportunities that we have never witnessed before and may never witness again. Entrepreneurs and investors who get in on the ground floor now could reap the benefits for generations to come.” says Alex Rogers, founder and CEO of the International Cannabis Business Conference.

The International Cannabis Business Conference is the leading cannabis B2B event series on the planet, with previous conferences occurring in several countries on multiple continents. The event series is owned and operated by cannabis advocates who believe in celebrating cannabis culture, in addition to providing world-class cannabis industry education and networking opportunities.

It is becoming increasingly difficult to gain an edge on the competition in the emerging international cannabis industry, and people need to get their ideas, products, or services in front of the right people at the right time.

With executives, entrepreneurs, investors, policymakers, and industry service providers converging from across the planet, the International Cannabis Business Conference B2B trade show event in Berlin is the perfect place to put cannabis ideas on the global cannabis stage.

Over 5,000 cannabis leaders from over 80 countries are expected to be represented at the conference in Berlin and that includes representatives from every sector of the industry as well as leading international cannabis policymakers and industry service providers.

Bring your company to the International Cannabis Business Conference in Berlin to network with the best and take your industry pursuits to the next level. Secure your exhibitor and/or sponsorship slot now before the event sells out.

The Talman House Elevates European Cannabis Investment Opportunities At Iconic Munich Event

The Talman House hosted an exclusive event on November 8, 2024, at the prestigious Sofitel Munich Bayerpost. Attended by select members, this gathering offered unparalleled access to the latest data and insights on the European cannabis market, bringing together investors, industry leaders, and a diverse range of experts in a distinguished setting. Held in Munich’s historic former Bavarian Royal Post Office, the event facilitated invaluable networking and foresight for Talman House members.Peter Homberg The Talman Group Munich Germany 2024

Led by Alex Rogers, CEO of The Talman Group, and Jamie L. Pearson, international consultant for the New Holland Group, the event featured a lineup of pioneering speakers and subject-matter experts who shared insider perspectives on German and European cannabis regulations, trends, and investment opportunities. These sessions focused on strategic insights for the European market, and equipped members with a deeper understanding of this rapidly growing market.

The Talman Group Munich Germany 2024

The event opened with Max Narr, a prominent figure in Germany’s cannabis industry, who explored Germany’s transformative regulatory journey. From regulatory shifts to new pilot projects, Narr provided attendees with a unique perspective on the strategic opportunities within Germany’s evolving cannabis landscape.

In addition to Narr, a series of presentations were delivered by leading figures in the cannabis space, including:

Speakers:

  • Peter Homberg – Partner, Dentons & Head of European Cannabis Group
  • Kai-Friedrich Niermann – Founder, Kfn+ Law Office
  • Will Muecke – Co-Founding Managing Member, Artemis Growth Partners
  • Daniel Kruse – CEO, Synbiotic SE
  • Emily Fisher – Founder and CEO, Leafwell
  • David Hyde – Founder, Hyde Advisory & Investments
  • Dr. Draško Veselinovič – President of The Board, Slovenian Business & Research Association, Brussels, EU
  • Cornelius Maurer – Economist; Co-Founder and Member of the Board, Demecan
  • Giadha A. DeCarcer – Principal, Blue Onyx Horizons; Founder, New Frontier Data

Sharks:

  • George Bellow – Co-Founder, SOMAÍ Pharmaceuticals
  • Sergio Bejar Martinez – Cannabis Industry Pioneer and Entrepreneur
  • Giadha A. DeCarcer – Principal, Blue Onyx Horizons; Founder, New Frontier Data

Through a rich array of expert presentations, The Talman House underscored its commitment to delivering exclusive, high-impact opportunities that keep members at the forefront of European
cannabis investment. Attendees departed better suited and inspired to take advantage of Europe’s evolving cannabis market.

Sharks The Talman Group Munich Germany 2024

The next gathering will take place on February 21st, 2025, at the Dolder Grand in Zurich, Switzerland, presenting yet another unique opportunity for members to gain valuable insights, network with industry leaders, and stay ahead in the cannabis investment landscape.

For more information on membership and upcoming events, please visit The Talman Group’s website. Below is a recap video of The Talman House’s Munich event:

Brazil’s Medical Cannabis Market Increased By 22% In 2024

According to a new market report by Kaya Mind, Brazil’s emerging medical cannabis market is projected to increase by a projected 22% by the end of 2024. The market report estimates that Brazil’s medical cannabis market is worth roughly BRL 832 million ($142 million).

Kaya Mind estimates that Brazil is now home to about 672,000 medical cannabis patients, which is a 50% increase compared to 2023. The market researchers estimate that only one-third of those patients currently make their purchases legally through the nation’s pharmacies and another 22% access medical cannabis products through collectives.

According to leading international cannabis economist Beau Whitney, the overall region’s growing cannabis market is worth a considerable amount of money.

“Central and South America together are an $8 billion total market; however, its low-cost manufacturing and drive towards EU GMP and GAP certifications is making the region an attractive source of supply for the EU.” Whitney stated in a recent newsletter.

Whitney’s analysis was originally provided as part of his presentation at the inaugural Andean Hemp and Cannabis Trade Summit in October where he presented on the Central and South American hemp and cannabis markets.

In addition to the overall market value analysis, Whitney Economics also provided the following market information:

  • Five countries in Central and South America make up 89% of the regional demand
  • Brazil is home to the largest domestic market ($2.5 billion)
  • Total Central and South American market demand requires 6.3 million pounds of cultivated output
  • Peru is an estimated $0.8 – $2.2 billion domestic market
  • Peru’s hemp industry has strong opportunities in fibers, grains, and isolated cannabinoids

Brazil’s Superior Court of Justice recently ruled that cultivating, processing, and selling industrial hemp for medical and pharmaceutical uses is legal in Brazil. The decision will eventually increase options for the nation’s suffering patients.

“While the ruling is a significant victory for the medical cannabis community, Justice Regina Helena Costa emphasized that the court’s decision was limited to health-related applications.” reported Benzinga in its initial coverage of the landmark decision.

Additionally, Brazil’s National Health Surveillance Agency recently decided to amend Ordinance SVS/MS 344/1998 to allow the regulation of medical cannabis products for animals by the Ministry of Agriculture and Livestock.

Veterinarians who are approved by the nation’s Federal Council of Veterinary Medicine may prescribe registered cannabis-based medications to animals. A study from December 2022 conducted by researchers in Brazil found that, at the macro level, cannabis appears to be safe for pets, especially cannabidiol, as long as it’s administered in the right dosage level.

“The review was systematically performed in Medline (via Pubmed®) and Latin American and Caribbean Health Sciences Literature (LILACS) databases, with period restriction (between 1990 and 2021). The qualified articles (n=19), which met the previously established inclusion criteria, were critically evaluated.” stated the researchers about their study.

“Based on the literature review, it is possible to infer safety in the administration of cannabis-based products for the treatment of dogs, especially products rich in cannabidiol (CBD), free or with low concentrations of tetrahydrocannabinol, under the conditions evaluated. In addition, CBD products potentially promote improved quality of life and reduce pain perception in animals affected by canine osteoarthritis.” the researchers also stated.

“Finally, owing to the lack of large-scale and robust clinical research studies, the performance of clinical trials, considering the individual characteristics of each cannabis-based product (composition, concentration, nature of adjuvants, dosage form, route of administration), is strongly encouraged.” the researchers concluded.

Cannabis Legalization Would Bring France Nearly €3.4Bn In Taxes And Savings

According to the European Union Drugs Agency, France has the highest rate of cannabis consumption on the European continent. Whereas adult-use cannabis policy modernization efforts have spread to Malta, Luxembourg, and Germany, and to a lesser extent the Netherlands and Switzerland, recreational cannabis remains illegal in France.

An escalation of violence linked to organized crime in France has led to recent calls by a parliamentary group for the European nation to legalize cannabis for adult use. La France Insoumise (LFI) has criticized the government’s current approach to cannabis policy.

“According to the unveiled “fight plan,” the government’s repressive response is not only insufficient, but it fuels insecurity, pushing citizens and officials into a cycle of violence.” stated Newsweed in its local reporting. “LFI advocates for a comprehensive, community-based approach to combating organized crime in France, including the legalization of cannabis.”

A previous study by an economic advisory board within the nation’s prime minister’s office determined that the French government spends roughly €570m annually on cannabis prohibition enforcement. The study recommended that France adopt adult-use cannabis legalization and launch a regulated recreational industry.

Emmanuelle Auriol, a professor at the Toulouse School of Economics who authored the study’s report and findings, estimated that such a policy change could create as many as 80,000 new jobs, and generate €2.8bn in taxes annually.

France does have a limited operational medical cannabis experimental program. In March 2021, France launched a limited medical cannabis experiment involving between 2,000 and 3,000 suffering patients to gain insight into crafting national medical cannabis policies and regulations.

The French medical cannabis experiment received initial approval from the federal Senate back in 2019, however, the launch of the trial was delayed until the spring of 2021 due to various reasons.

Initially slated for two years, France’s medical cannabis experiment was eventually granted a one-year extension and was set to end in 2024. The program is now expected to end in 2025.

According to a recent newsletter sent out by international cannabis economist Beau Whitney of Whitney Economics, France is home to the largest total addressable cannabis market in the European Union with a value of $11.3 billion (midpoint).

MJBizCon Comes Back To Las Vegas On December 3-6

MJBizCon, the top cannabis industry event in the United States, is coming back to Las Vegas next week on December 3rd-6th, 2024. The event, which is often described as ‘the Super Bowl of Cannabis’ is a must-attend for anyone serious about succeeding in the emerging legal U.S. industry.

Many members of the United States cannabis industry measure their calendar years from MJBizCon to MJBizCon, and rightfully so. In many ways, the event serves as a U.S. cannabis industry family reunion, with people from all over the country converging at MJBizCon to see their friends and colleagues and forge new relationships and partnerships.

Next week’s event is the thirteenth installment of the conference and will be bigger and better than ever. I was personally in attendance at the first-ever MJBizCon back in 2012, with the inaugural MJBizCon being held in Denver, Colorado the day after the state’s voters approved the nation’s first adult-use legalization measure.

I had attended other cannabis events over the years up to that point, but it was readily apparent that something special was beginning at the first MJBizCon event. Since that time, the legal industry in the United States has exploded, experiencing exponential growth across the country and the rise of the legal industry in the U.S. was paralleled by the rise of the now iconic MJBizCon.

79% of people living in the United States now live in a county with at least one regulated cannabis dispensary according to an analysis by the Pew Research Center. The Pew Research Center also found the following:

  • 74% of people in the U.S. live in a state where recreational or medical cannabis is legal
  • There are nearly 15,000 cannabis dispensaries in the U.S.
  • California has the most overall dispensaries (3,659)
  • Oklahoma has the most dispensaries per capita (36 dispensaries for every 100,000 residents)

MJBizCon has experienced such tremendous growth over the years, going from hundreds of attendees back in 2012 to tens of thousands in recent years, that the event has long since moved to its current home in Las Vegas, Nevada to accommodate the growing number of attendees and exhibitors. This year’s MJBizCon will feature (including but limited to):

  • Pre-show forums focused on finance and marketing, science and psychedelics, and women’s leadership
  • Expo Hall featuring cultivation products and services, processing, packaging and lab services, retail, and other B2B services
  • 3 full days of informative conference education sessions
  • Over 60 popular networking event opportunities

MJBizCon 2024 is expected to host over 30,000 cannabis entrepreneurs, over 1,400 exhibitors, and over 200 industry speakers.

Members of the International Cannabis Business Conference’s team will be in attendance, and we are encouraging all of our followers in the United States to consider attending MJBizCon 2024 in Las Vegas next week from December 3rd to 6th. You can purchase your tickets at this link here, and make sure to use the special promo code ‘MIPMXAB87’ to receive a special 10% discount!

The emerging legal cannabis industry in the United States is projected to add roughly $112 billion to the nation’s economy in 2024 according to an analysis by MJBiz Daily. The projection is part of the company’s 2024 MJBiz Factbook.

Czech General Practitioners To Start Prescribing Medical Cannabis In 2025

Starting on April 1, 2025, general practitioners (GPs) in the Czech Republic will be authorized to prescribe medical cannabis to suffering patients. The policy change is a result of a new decree from the nation’s Ministry of Health.

“The decree allows GPs to prescribe medicinal cannabis for chronic, intractable pain,” Ministry spokesperson Ondřej Jakob said according to local reporting by Prague Morning (translated from Czech to English).

Medical cannabis was first legalized in Czechia in 2013, however, only specialists can currently prescribe it resulting in roughly 8,000 patients receiving legal access.

“If GPs can prescribe opiates such as morphine, it is logical they should also be allowed to prescribe medicinal cannabis,” stated Petr Šonka, Chairman of the Association of GPs of the Czech Republic according to Prague Morning.

According to a recent study conducted by researchers from Ukraine and France, and published by the U.S. National Institute of Health, 57 countries have adopted medical cannabis legalization measures.

Per the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), nearly 30% of Czech adults have consumed cannabis at least once in their lifetimes and 11.1% report having consumed cannabis within the last year. The average rate for once-a-year consumption across Europe is 8% according to EMCDDA data.

The Czech Republic’s cabinet recently approved a plan that would permit adults in the European nation to cultivate multiple plants in their private residences and possess a personal amount of cannabis.

The plan, which would legalize the cultivation of up to three cannabis plants and set a maximum possession limit of 50 grams of cannabis, was originally introduced by the Czech Republic’s Ministry of Justice back in September 2024.

In October 2022, an expert study was commissioned by the Czech Republic Pirate Party and it found that a taxed and regulated cannabis industry would generate “tax revenue from EUR 26.5 million to EUR 73 million per year.”

Australian Medical Cannabis Sales Quadrupled In The Last Two Years

Medical cannabis sales in Australia have quadrupled during the last two years, with Australians expected to spend an estimated $1 billion on medical cannabis this year. Medical cannabis was first legalized in Australia in 2016.

“The Pennington Institute’s Cannabis in Australia report has revealed spending has skyrocketed from $230 million two years ago to a predicted $1 billion by the end of this year.” 9News stated in its local coverage.

“The spending correlates with usage, which jumped from just 3.9 per cent of survey respondents in 2019 to almost 30 per cent admitting they use prescription marijuana.” the outlet also reported.

Australia’s Senate voted on an adult-use cannabis legalization measure this week. According to the Australian Greens Party, which introduced the measure, the measure was “blocked by the Labor and Coalition parties in a 13 to 24 vote against progress.”

“We took a big step today from treating cannabis as part of the failing ‘war on drugs’ and instead putting forward a model that is safer, reduces harms and delivers for the millions of Australians who just want us to legalize it!” Greens Senator and Justice Spokesperson David Shoebridge said in a media release.

“The support for this bill across the community is enormous and it’s why we know cannabis legalisation in this country is inevitable.” Shoebridge also stated. “The Labor and Coalition parties joined together to try and hold Australia back in the 1950’s by blocking this desperately needed reform.”

Currently, cannabis is legal for adult use at a national level in Uruguay, Canada, Malta, Luxembourg, Germany, and South Africa. Cannabis is also legal for recreational use in two dozen states in the U.S., and regional adult-use cannabis commerce pilot trials are operating in the Netherlands and Switzerland.

“Government data shows 8.8 million of adult Australians have consumed cannabis. The Labor and Liberal parties are happy to call all of these people criminals. That’s a bloody disgrace.” Senator Shoebbridge said. “My office keeps hearing from people using cannabis to deal with anxiety or pain, or just to relax. We think that adults should have the right to do just that.”

“If choosing cannabis instead of products from pharmaceutical corporations is working for you, as it does for many Australians, then you should have that choice.” Shoebridge also said. “If you’d rather have a brownie than a beer, or a gummy than a cigarette, of course you should be allowed to do that.”